Lv1
68 积分 2023-06-25 加入
Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: MAINTAIN Trial
3天前
已完结
S903 Efficacy and Safety of Camrelizumab Plus Apatinib for Esophageal Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis
7天前
已完结
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
14天前
已完结
Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): A single-arm, phase II study
16天前
已完结
Survival after esophagectomy for metastatic esophageal cancer: should the role of surgery be reconsidered?
16天前
已关闭
Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial
16天前
已完结
High-Dose Morphine and Methadone in Cancer Patients
25天前
已完结
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
Heterogeneity of Histological Transformation Events in Waldenström's Macroglobulinemia (WM) and Related Disorders
1个月前
已完结
Discovery and preclinical evaluations of TQB3616, a novel CDK4-biased inhibitor
1个月前
已完结
皖公网安备34019202002308
